Monte Rosa Therapeutics (GLUE) grants director Jan Skvarka 25,800 options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Monte Rosa Therapeutics director Jan Skvarka received a grant of 25,800 stock options for common stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. Following this grant, he holds options for 25,800 shares. The options vest in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, as long as he continues serving the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Skvarka Jan
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 25,800 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 25,800 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Stock options granted: 25,800 options
Exercise price: $17.10 per share
Expiration date: June 11, 2036
+3 more
6 metrics
Stock options granted
25,800 options
Grant to director Jan Skvarka on June 11, 2026
Exercise price
$17.10 per share
Exercise price for granted stock options
Expiration date
June 11, 2036
Option term end date
Underlying shares
25,800 shares
Common stock underlying granted options
Post-grant option holdings
25,800 options
Total options held following this transaction
Vesting date trigger
June 11, 2027
Latest vesting date, or earlier at next annual meeting
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, vest and become exercisable, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 17.1000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-11T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest and become exercisable financial
"The shares subject to this option shall vest and become exercisable in full"
annual meeting of stockholders financial
"the Issuer's next annual meeting of stockholders"
FAQ
What did Monte Rosa Therapeutics (GLUE) disclose in this Form 4 filing?
Monte Rosa Therapeutics reported that director Jan Skvarka received a grant of 25,800 stock options. These options give him the right to buy common shares at a fixed exercise price, functioning as equity-based compensation rather than an open-market stock purchase or sale.
How many stock options did Jan Skvarka receive from Monte Rosa Therapeutics (GLUE)?
Jan Skvarka received 25,800 stock options linked to Monte Rosa Therapeutics common stock. Each option represents the right to buy one share, so the grant covers 25,800 underlying shares once the options vest and are exercised, subject to the plan’s terms.
What is the exercise price and expiration date of the GLUE options granted to Jan Skvarka?
The granted options have an exercise price of $17.10 per share and expire on June 11, 2036. This means Skvarka can choose to buy shares at $17.10 any time after vesting and before the June 11, 2036 expiration date, if he remains eligible.
When do Jan Skvarka’s Monte Rosa Therapeutics (GLUE) options vest?
The options vest and become exercisable in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders. Vesting is conditioned on his continued service with Monte Rosa Therapeutics through that vesting date or meeting.